NEWSROOM | Galderma

Galderma intends to buy back approximately 2.4 million shares in the context of the accelerated bookbuild offering by EQT, ADIA and Auba

Galderma delivers record first quarter net sales of 1.129 billion USD, including strong performance from two launches with blockbuster potential, and confirms full-year guidance

Galderma shareholders approve all Annual General Meeting proposals

Galderma launches "Scratch Resistance" campaign to validate the physical and emotional burdens of atopic dermatitis

Galderma launches new ALASTIN Restorative Skin Complex with Next Generation TriHex Technology®

Galderma launches Sculptra® in China, further fueling its growth into one of the fastest growing aesthetics markets

Galderma publishes its 2024 Annual Report and the invitation to its first Annual General Meeting

AMWC 2025: Galderma’s Scientific Presentations

AMWC 2025: Galderma pushes the innovation frontier with updates from its unparalleled portfolio designed to meet the needs of the aesthetic community

Galderma’s Differin is helping destigmatize acne care with first in category Roblox experience

Galderma successfully placed an inaugural EUR 500 million single tranche Eurobond and new dual tranche CHF 435 million CHF bonds

Galderma delivers 2024 record net sales of 4.410 billion USD, up 9.3% year-on-year at constant currency1, and record Core EBITDA of 1.031 billion USD, while preparing to accelerate its growth trajectory into 2025 and beyond